Forgot Password?
Return to Course Listing

CME: Metastatic cutaneous melanoma: Updates from the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

Activity Description / Statement of Need:

In this online, self-learning activity:

Melanoma is a tumor of the melanocytes primarily occurring in the skin. The fifth most common cancer in the U.S., it occurs in over 100,000 people annually and is attributable to over 8,200 deaths each year.  It is also one of the most common cancers in young adults. The five-year survival rate from diagnosis overall is 80% to 99% for patients with early stages of the disease, depending on tumor thickness. However, in patients in whom the disease that has spread to adjacent lymph nodes or tissues, the five-year survival drops to 71%, and for those with distant metastases (five percent of cases are diagnosed at this stage), the five-year survival is 32%, representing an area of ongoing clinical need.

Target Audience:

HCPs including: medical oncologists and dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with malignant melanoma.


Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

This activity is free of charge.


Release Date: January 29, 2025 -- Expiration Date: January 29, 2026

Faculty: Allison Betof Warner, MD, PhD

Agenda

Faculty introduction, disclosures

Introductory content and review of metastatic cutaneous melanoma

  • Major findings from ESMO 2024, including clinical trial data  relevant to both community and health-system practice and recognized barriers to implementing those findings in practice
  • Adjuvant Therapy
    • CheckMate 76K
    • KEYNOTE-716
  • Neoadjuvant Therapy
    • NADINA
    • International Neoadjuvant Melanoma Consortium pooled data update
  • Metastatic Disease
    • Long-term follow-up for front line therapy (KEYNOTE-006, CheckMate 067)
    • IGNYTE

Summary and concluding remarks

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at the ESMO 2024 annual meeting relating to metastatic cutaneous melanoma (inclusive of disease diagnosis, progression, prognosis, evaluation of degree therapeutic success, quantifying benefit and risk of disease progression and therapeutic, and emerging therapies), and apply them to patient cases.
  • Understand the magnitude of benefit of adjuvant therapy for stage IIB-IIC melanoma.
  • Evaluate updated data in neoadjuvant therapy for advanced melanoma.
  • Characterize long-term survival data for first-line immunotherapy for advanced melanoma.
  • Analyze updated data for the oncolytic virus RP1 from the IGNYTE trial.

Accreditation

ACCME Activity #202895831

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours  of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-25-007-H01-P. This is an Application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Associates: The American Academy of Physician Associates (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Associates (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Allison Betof Warner, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology, Stanford University School of Medicine, has received financial compensation from Adaptimmune, Bristol Myers Squibb, Immatics, IO Biotech Iovance Biotherapeutics, Lyell Immunopharma, Novartis, Merck, Pfizer, and Obsidian Therapeutics as a consultant; in addition to grant/research work from Bristol Myers Squibb, Iovance Biotherapeutics, Lyell Immunopharma.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

The state of prostate cancer treatment: advances in approach for advanced disease

Advanced systemic mastocytosis: from recognition to treatment

Tackling a sore subject: best practices in the identification and management of psoriatic arthritis (PsA)

A critical appraisal of present and emerging management approaches to moderate to severe plaque psoriasis in adults: going beyond skin-deep